GSK:NYSE
GSK plc
46,96 $
arrow_upward
+0,98%(+0,45) 1D
12 հոկ, 13:17:46 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
46,70 $
High
47,00 $
Low
46,31 $
Mkt. cap
94,55 մլրդ
Avg. vol.
3,91 մլն
Volume
6,01 մլն
Dividend
3,87%
Quarterly dividend
0,45 $
Ex-dividend date
13 օգս, 2026 թ.
P/E ratio
15,04
52-wk high
61,70 $
52-wk low
42,84 $
EPS
3,12 $
Beta
0,25
Shares outstanding
2,16 մլրդ
No. of employees
67 հզր
Open
46,70 $
High
47,00 $
Low
46,31 $
Mkt. cap
94,55 մլրդ
Avg. vol.
3,91 մլն
Volume
6,01 մլն
Dividend
3,87%
Quarterly dividend
0,45 $
Ex-dividend date
13 օգս, 2026 թ.
P/E ratio
15,04
52-wk high
61,70 $
52-wk low
42,84 $
EPS
3,12 $
Beta
0,25
Shares outstanding
2,16 մլրդ
No. of employees
67 հզր
News stories
From web sources and news partners
Zacks
·
1 ժամ առաջ
Is the Options Market Predicting a Spike in GSK Plc Stock?
TipRanks
·
2 ժամ առաջ
GSK Executives Reinvest Dividends in Routine Share Acquisitions
Endpoints News
·
2 ժամ առաջ
GSK to invest $800M for new R&D, manufacturing hub in Pennsylvania
ad-hoc-news.de
·
4 ժամ առաջ
GSK stock costs EUR 20.89 with USD 93.2 billion market value
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66,8 հզր
Founded27 դեկ, 2000 թ.
Headquarters-
Sector-
Websitegsk.com